ideasIdea
Stop failing trials earlier with pre-registered aggressive futility rules
Many big trials continue for years after the data already show the drug is unlikely to work. Agreeing in advance to stop earlier when the odds look bad would spare patients and free money for better ideas.
Phase 3 protocols include non-binding but pre-registered futility boundaries at 30-50 percent information (predictive probability of success below a threshold), evaluated by independent monitoring committees, with public reporting of the interim decision. Sponsors commit to the rule in the registry entry, reducing the temptation to continue for commercial reasons.
Hypothesis
Trials with pre-registered aggressive futility rules will stop negative studies a median of 12 months earlier and expose 30 percent fewer patients to ineffective experimental arms, with a negligible increase in falsely abandoned effective drugs.
Rationale
Retrospective analyses of negative phase 3 trials show most would have met conventional futility criteria at interim, yet sponsors often lack pre-specified rules or set them conservatively.
What would test it
Simulate aggressive futility rules on completed negative phase 3 trials with interim data available and quantify time and patients saved versus false stops of positive trials.
Maturity
speculative
Who has to act
industry
Cost to try
Small (under $1M)
Years to first evidence
2
Bottlenecks it attacks
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.